Casey Tansey Buys 16,441 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 16,441 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average price of $12.07 per share, for a total transaction of $198,442.87. Following the completion of the purchase, the director owned 318,332 shares of the company’s stock, valued at approximately $3,842,267.24. This represents a 5.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Mobia Medical Stock Performance

Mobia Medical stock opened at $10.61 on Friday. Mobia Medical, Inc. has a 1 year low of $10.19 and a 1 year high of $15.29. The firm has a market capitalization of $353.21 million and a price-to-earnings ratio of -0.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The business has a 50 day simple moving average of $12.31.

Mobia Medical (NASDAQ:MOBI) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The business’s revenue was up 102.4% on a year-over-year basis. As a group, equities analysts predict that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Analysts Set New Price Targets

MOBI has been the topic of a number of analyst reports. Bank of America began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. The Goldman Sachs Group initiated coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, BTIG Research reissued a “buy” rating and issued a $19.00 price objective on shares of Mobia Medical in a research report on Wednesday, August 12th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.